Physician profile
Rufaat Mando
NPI 1205242591
$8,409.66
in general payments reported to CMS, 2019-2025
28 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $547 · 2021: $1,962 · 2022: $2,134 · 2023: $2,228 · 2024: $812 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,149 · Education: $34.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,148.62 |
| Education | $34.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,199.92 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,183.20 | 2019-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $948.72 | 2019-2024 | Stelara, Simponi Aria, Remicade |
| Celgene Corporation | $534.68 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $529.04 | 2020-2024 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $514.99 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $498.06 | 2021-2023 | Sutab |
| Qol Medical, LLC | $413.54 | 2021-2024 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $284.97 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $239.79 | 2020-2023 | Linzess |
| Redhill Biopharma INC. | $179.53 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $153.98 | 2023-2025 | Dupixent |
| Covidien LP | $141.09 | 2019 | |
| Phathom Pharmaceuticals, INC. | $124.45 | 2024 | Voquezna |
| Pfizer INC. | $95.52 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $50.60 | 2022-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $47.84 | 2020-2021 | |
| Organon LLC | $39.98 | 2023-2024 | Hadlima |
| Sandoz INC. | $33.66 | 2023 | |
| Ferring Pharmaceuticals INC. | $33.02 | 2021-2022 | |
| Ardelyx, INC. | $32.82 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $26.85 | 2022 | |
| Olympus America INC. | $20.52 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $20.15 | 2024 | Bylvay |
| Merck Sharp & Dohme LLC | $17.21 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.16 | 2024 | Givlaari |
| Capsovision, INC. | $14.65 | 2024 | Capsocam Plus |
| Medtronic, INC. | $13.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rufaat Mando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.